Navigation Links
Omar S. Manejwala, MD Speaks Out Nationally on Diprivan/Propofol Abuse
Date:7/17/2009

In response to the recent media attention on Diprivan (Propofol) abuse, the Farley Center at Williamsburg Place, one of the nation's leading addiction treatment centers, has offered to provide expert consultation about this rare disorder.

Williamsburg, VA (PRWEB) July 17, 2009 -- In response to the recent media attention on Diprivan (Propofol) abuse, the Farley Center at Williamsburg Place, one of the nation's leading addiction treatment centers, has offered to provide expert consultation about this rare disorder. Omar S. Manejwala, M.D., Associate Medical Director for the Farley Center is one of a handful of physicians highly experienced in this area and has appeared nationally recently on programs such as the Early Show on CBS.

Diprivan, is a widely used intravenous sedative medication that is used both for procedures (such as in surgeries or colonoscopies) and for non-procedural sedation. It has been around since the 1980's and is very widely used. It is often described as "milk of amnesia" or "milk of the ICU.

"I've worked with many practitioners who prefer to use it because of its rapid onset and the ability to carefully titrate doses and the rapid recovery afterwards. It has more than a couple of decades of safe, effective use when used appropriately." states Dr. Manejwala.

But only a few cc's more than what's required can trigger fatal respiratory arrest and because Diprivan is such a short-acting medication, heavy abusers must inject it frequently to stay high. As many as 50 to 100 times during a using session is not unheard of. 40% of residents who reportedly abused the anesthetic died from their use of the peril of Diprivan's exquisitely narrow therapeutic window.

Many individuals who are addicted to Diprivan also suffer from Post-Traumatic Stress Disorder (PTSD). Most commonly, these individuals are initially attempting to self-medicate refractory, persistent insomnia. This insomnia can be due to any number of causes including depression, PTSD, alcoholism or addiction to other agents. With repeated self-administration, these individuals develop the brain disease of addiction and their use becomes compulsive, rather than self-medicating.

Abuse in the Healthcare Industry

Dr. Manejwala indicates that, in his clinical experience, a high percentage of Diprivan abusers are health care practitioners--usually anesthesiologists, nurse anesthetists or operating room technicians. Research indicates that one in five academic anesthesiology training programs reported at least one case of abuse by physicians or other healthcare workers over the past decade. The reported incidence of Propofol abuse has risen fivefold over the last 10 years. While no specific study of outcomes in Diprivan addiction has been conducted, our clinical experience supports strong outcomes in this cohort when appropriate treatment modalities are employed. Dr. Manejwala recommends state-of-the-art addiction treatment for Diprivan addiction by a facility with specific experience treating professionals with Diprivan addiction, and has seen strong outcomes from this approach.

"It's very difficult for individuals who abuse Diprivan to identify with other addicts, and this identification is critical to good outcomes. Since Diprivan addiction is so infrequent, it is really important that Diprivan dependent patients seek treatment at centers that have experience treating this disorder."

The Farley Center at Williamsburg Place is a leading addiction treatment program in the nation known for its work in treating individuals who have Substance Use Disorders, and offers intensive, in-depth psychotherapeutic treatment, safe detoxification, as well as educational and experiential approaches to assist people transition into recovery. Many patients have been diagnosed with complicating medical conditions, co-occurring psychiatric illnesses and/or personality disorders. Considered the leader in treating professionals and working with Physicians Health and Lawyers Assistance Programs, The Farley Center at Williamsburg Place takes pride in being able to prepare the professional to return to their chosen field safely and in recovery.

Dr. Omar S. Manejwala is a board-certified addiction psychiatrist and is also board-certified by the American Board of Addiction Medicine. A graduate of the University of Maryland School of Medicine, he completed his internship and residency in psychiatry at Duke University Medical Center, where he also served as the Executive Chief Resident.

Active in ASAM, having held several leadership positions at the North Carolina Psychiatric Association and the North Carolina Society of Addiction Medicine, Dr. Manejwala is also certified Medical Review Officer. He is a frequent guest speaker on state of the art approaches to modifying traditional "rehab" treatment for alcoholism and drug addiction.

For more information, please visit www.farleycenter.com to learn more about the diagnosis of Diprivan abuse and addiction treatment.

Contact:
Gina de Peralta Thorne, MS
Director of Business Development
The Farley Center at Williamsburg Place
gthorne(at)farleycenter.com
800-582-6066

###

Read the full story at http://www.prweb.com/releases/FarleyCenter/Diprivan/prweb2653044.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. General Colin Powell Speaks Out for Prostate Cancer Prevention
2. Women for Women International Congolese Country Director, Christine Karumba, Speaks Out About the Rape Epidemic in the Democratic Republic of the Congo.
3. Autism Speaks Applauds Supreme Court Decision Upholding Families Right to Challenge IEPs Without First Trying Out School District Proposed Placement
4. CBM USA stands up and speaks out to world leaders on the International Day for the Eradication of Poverty
5. San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism
6. National Institute on Drug Abuse Director Nora Volkow Speaks about the Dangers of Narcotics on Azteca Americas Political Forum Issues: Caras y Voces
7. Massachusetts Teacher Facing Unaffordable Mandatory Health Insurance Speaks Out Against CA Mandate Proposal
8. AAFPRS Speaks to the Safety of BOTOX(R) Cosmetic
9. ToysRUs Kicks Off Fundraising Campaign to Benefit Autism Speaks
10. Autism Speaks to Celebrate World Autism Awareness Day with Day-Long Series of International Events on April 2
11. Consumer Advocate Speaks Out Against Bill Allowing Invasions of Medical Privacy; Author Received $21k from Bill Benefactors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... PITTSBURGH, PA (PRWEB) , ... December 09, 2016 , ... ... treatments," said an inventor from Winchester, Va. "I thought that if the nebulizer had ... their treatments rather than fearing them." , He developed the patent-pending NEBY to avoid ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Medical Center has been recognized for adherence to the highest standards of ... medical accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... -- Research and Markets has announced the addition of ... Type, Application, Usability - Forecast to 2025" report to their ... , , ... to grow at a CAGR of around 3.2% from 2015 to ... include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in ...
(Date:12/8/2016)...   TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...
Breaking Medicine Technology: